The company estimates a 8.4% turnover hike, to RON348 million, according to the document that will be discussed Tuesday by shareholders.
Zentiva also plans to pay out its shareholders total dividends worth RON30 million, 50% higher on the year and nearly three quarters of its 2013 net profit of RON40.3 million.
The company’s net profit rose 25% last year to RON40.3 million, while the turnover rose 20% to RON291 million.
For this year, the company plans RON7 million investments in facilities and production equipment.
According to the latest available data, French group Sanofi-Aventis owns 81.6% of Zentiva Romania’s shares.
On the Romanian market, the French drugmaker operates through two separate units: Sanofi-Aventis Romania and Zentiva Romania.
Sanofi-Aventis ranked second on the domestic pharmaceutical market last year, with a share of 7% and sales of RON827.5 million last year, according to market researcher Cegedim.
On the Bucharest stock exchange Monday, Zentiva traded flat at RON1.15 a share. (EUR1=RON4.4549)